- Home
- GALT vs EICA Comparison
GALT vs EICA Comparison
Compare GALT & EICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GALT | EICA |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.3M | N/A |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GALT | EICA |
|---|---|---|
| Price | $6.54 | $24.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 465.8K | N/A |
| Earning Date | 11-14-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | N/A |
| 52 Week High | $6.66 | N/A |
Technical Indicators
Market Signals| Indicator | GALT | EICA |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 44.99 |
| Support Level | $5.10 | $24.55 |
| Resistance Level | $6.32 | $24.70 |
| Average True Range (ATR) | 0.56 | 0.07 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 93.06 | 26.67 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About EICA Eagle Point Income Company Inc. 5.00% Series A Term Preferred Stock due 2026
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.